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Summary
 
Objective
 
Adult onset GH deﬁciency (GHD) is characterized by
abnormalities of serum lipoprotein proﬁles and GH replacement
results in favourable alterations in serum total and low density lipo-
protein (LDL)-cholesterol. Preliminary evidence has indicated that
the effect of GH replacement in this respect may be additive to that
of HMG CoA reductase inhibitor (statin) therapy. We have examined
this possibility during prospective follow-up of adult onset hypo-
pituitary patients enrolled in KIMS (Pﬁzer International Metabolic
Database), a pharmacoepidemiological study of GH replacement in
adult hypopituitary patients.
 
Design L
 
ipoprotein proﬁles were measured centrally at baseline
and after 12 months GH replacement therapy.
 
Patients
 
Sixty-one hypopituitary patients (30 male, 31 female) on
maintenance statin therapy (mean 2·5 
 
±
 
 2·7 SD years before GH)
(statin group – SG) and 1247 (608 male, 639 female) patients not
on hypolipidaemic therapy (nonstatin group – NSG) were studied.
All patients were naïve or had not received GH replacement during
the 6 months prior to study. Patients who developed diabetes
mellitus during the ﬁrst year of GH therapy or in the subsequent
year and those with childhood onset GHD were excluded from this
analysis. An established diagnosis of diabetes mellitus was present in
18% SG and 4·4% NSG at baseline.
 
Measurements
 
Serum concentrations of total, high density lipo-
protein (HDL)-cholesterol, triglycerides and IGF-I were measured
centrally in all patients and LDL-cholesterol was estimated using
Friedewald’s formula.
 
Results
 
The relative frequency of various statin use was simvastatin
52% (15·8 
 
±
 
 8·1 mg, mean 
 
±
 
 SD), atorvastatin 30% (14·4 
 
±
 
 7·8 mg),
pravastatin 9·8% (31·6 mg 
 
±
 
 13·9 mg), lovastatin 6·6% (17·5 
 
±
 
 5 mg)
and ﬂuvastatin 1·6% (40 mg). Baseline serum total and LDL-
cholesterol (mean 
 
±
 
 SD) were 5·2 
 
±
 
 1·4 and 3·1 
 
±
 
 1·3 mmol/l in SG
and 5·8 
 
±
 
 1·2 and 3·7 
 
±
 
 1·0 mmol/l in NSG, respectively (
 
P
 
 
 
<
 
 0·0001,
SG 
 
vs
 
. NSG). After 12 months GH replacement (SG: 0·32 
 
±
 
 0·17 mg/day;
NSG: 0·38 
 
±
 
 0·1 mg/day) serum total and LDL-cholesterol decreased
by a mean (
 
±
 
SD) of 0·48 (
 
±
 
 1·25) mmol/l (
 
P
 
 
 
<
 
 0·0004) and 0·53
(
 
±
 
 1·08) mmol/l  (
 
P
 
 
 
<
 
  0·0001) in SG and by 0·30 (
 
±
 
 0·89) mmol/l
(
 
P
 
 
 
<
 
  0·0001) and 0·28 (
 
±
 
 0·80) mmol/l  (
 
P
 
 
 
<
 
  0·0001) in NSG,
respectively. There were no signiﬁcant changes in HDL-cholesterol
or triglycerides in either group (SG 
 
vs
 
. NSG: NS). A relationship
between LDL-cholesterol at baseline and the decrease in LDL-
cholesterol after 12 months GH was evident in both groups (SG:
 
R
 
 
 
=
 
 –0·54, 
 
P
 
 
 
<
 
 0·001;  NSG: 
 
R
 
 
 
=
 
 –0·4, 
 
P
 
 
 
<
 
  0·001) and a similar
relationship for cholesterol was observed.
 
Conclusions
 
These data indicate that GH replacement exerts
additional beneﬁcial effects on lipoprotein proﬁles in patients on
maintenance statin therapy, conﬁrming that the effects of these inter-
ventions are complementary rather than exclusive.
(Received 20 March 2007; returned for revision 2 April 2007; ﬁnally 
 
revised 23 April 2007; accepted 23 April 2007)
 
Introduction
 
A number of retrospective studies have demonstrated that hypo-
pituitarism is associated with a signiﬁcant increase in standardized
mortality ratio, particularly in females
 
1–4
 
 and these ﬁndings have
been conﬁrmed in a subsequent prospective multicentre study.
 
5
 
 The
increase in mortality appears to be particularly related to cardio-
vascular and cerebrovascular disease.
 
1,3–5
 
 In all of these publications
a unifying characteristic was the high prevalence of untreated growth
hormone deﬁciency (GHD), with other deﬁciencies conventionally
replaced. This raises the possibility that the GHD state may predispose
to cardiovascular disease although other factors including aetiology
(especially craniopharyngioma) and untreated oestrogen deﬁciency
are likely to be additional and independent factors.
 
5
 
 Consistent with
a causal role for GHD in the pathogenesis of cardiovascular disease,
such deﬁciency is associated with an increased prevalence of cardio-
vascular risk factors including increased concentrations of total and
low density lipoprotein (LDL)-cholesterol, increased central adiposity,
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insulin resistance and glucose intolerance. Furthermore, these
abnormalities are signiﬁcantly improved by growth hormone
replacement therapy.
 
6–14
 
 Additional evidence favouring a speciﬁc
contribution from GHD to adverse cardiovascular risk comes from
studies comparing baseline characteristics and the effects of GH
replacement in patients with isolated GHD in comparison with more
generalized pituitary failure.
 
15,16
 
The beneﬁcial effects of GH replacement on serum lipoprotein
proﬁles are particularly evident in relation to LDL-cholesterol, the
durable decrement in which accounts for the changes in serum total
cholesterol observed.
 
13
 
 Subtle changes in high density lipoprotein
(HDL)-cholesterol may occur with prolonged treatment and
improvements in serum triglycerides may be evident in speciﬁc
aetiological groups and in patients with the highest pretreatment
levels.
 
17
 
 The efﬁcacy of 3-hydroxy-3-methylglutaryl coenzyme A (HMG
CoA) reductase inhibitor (statin) therapy in lowering serum LDL-
cholesterol concentrations begs the question as to whether there may
be an additive effect of these agents and GH replacement in GHD
hypopituitary patients. In terms of respective mechanism of action on
cholesterol metabolism, such an effect would be predicted and has
indeed been observed in a small number of patients in a single-centre
observational study.
 
13
 
 We have utilized data from KIMS (Pﬁzer Inter-
national Metabolic Database) to further elucidate this phenomenon.
 
Patients and methods
 
KIMS Database
 
KIMS is the Pﬁzer International Metabolic Database and pharmaco-
epidemiological survey of adult hypopituitary (GHD) patients
treated with GH replacement therapy (Genotropin®). Enrolment
into KIMS currently stands at approximately 12 000 patients from
28 countries. Following enrolment, patients are seen in local clinics
at a frequency determined by the treating physician but with one visit
per year being mandatory. At each visit, data are collected on speciﬁc
case record forms and entered into a central database. The quality
of data collection is monitored by clinical research representatives
according to Good Clinical Practice Guidelines and the accuracy of
data entry into the database is monitored by internal audit.
 
Patients and study design
 
Lipoprotein proﬁles were measured prior to and after 12 months GH
replacement therapy in 61 patients (30 males, 31 females) on stable
maintenance statin therapy (statin group, SG) and in 1247 patients
of similar mean age and range (608 males, 639 females) not on
hypolipidaemic therapy (nonstatin group, NSG). All patients were
enrolled between 1994 and 2004. Details of aetiological diagnosis,
additional hormone replacement therapy, prevalence of diabetes
mellitus and duration of statin use are provided in Table 1. The range
of speciﬁc statins used and dose schedules are given in Table 2. It is
noteworthy that diabetes mellitus was more prevalent in the SG
group (18% 
 
vs
 
. 4·4%) at baseline. Patients were either completely
naïve to GH replacement or had not received GH for at least
6 months prior to the study and the study was restricted to patients
with adult onset disease. Patients who developed diabetes mellitus
during the ﬁrst year of GH therapy or in the subsequent year were
excluded from this analysis (3 on statins and 31 not on hypolipidaemic
therapy). Doses of thyroid hormone replacement were constant
throughout the period of observation.
Aetiology SG (%) NSG (%)
Pituitary adenoma 66·6 72·1
Craniopharyngioma 6·4 6·6
Other pituitary/hypopituitary tumours 5·1 1·6
Cranial tumours 3·0 0
Extracranial malignancy 0·6 0
Other causes acquired GHD 13·6 18·0
Idiopathic GHD 4·7 1·6
Hormone replacement
TSH 70·8 68·8
ACTH 67·2 63·9
LH/FSH 78·3 78·7
ADH 23·4 16·4
Diabetes mellitus 4·4 18·0*
Duration of statin therapy before entry into KIMS† 2·6 ± 2·7 SD
†Only patients who were treated with statins for at least 1 year before entry into KIMS were included.
*P < 0·0001. GHD, growth hormone deﬁciency.
Table 1. Aetiology of hypopituitarism, additional 
hormone replacement, prevalence of diabetes 
mellitus in statin group (SG) and nonstatin group 
(NSG) and duration of statin use in SG
Table 2. Prevalence and dose range of individual statin preparations in statin 
group (SG)
Statin preparation Dose (mean ± SD; mg) Dose prevalence (%)
Simvastatin 15·8 ± 8·1 52·0
Atorvastatin 14·4 ± 7·8 30·0
Pravastatin 31·6 ± 13·9 9·8
Lovastatin 17·5 ± 5 6·6
Fluvastatin 40 1·6 
GH and statin therapy
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All patients had severe GHD as demonstrated by a peak serum
GH response of 
 
<
 
 9 mU/l  (
 
<
 
 3 
 
µ
 
g/l) during insulin, glucagon or
arginine testing.
 
Serum IGF-I assay
 
Until November 2002, serum IGF-I concentrations were determined
by radioimmunoassay (RIA) after acid-ethanol precipitation of IGF
binding proteins (Nichols Institute Diagnostics, San Juan Capistrano,
CA). Thereafter, a chemiluminescence immunoassay (Nichols Advan-
tage® System, Nichols Institute Diagnostics, San Juan Capistrano,
CA) was introduced.
 
18
 
 Long-term reproducibility, measured during a
time period of more than 1 year, showed a coefﬁcient of variation (CV)
of less than 9% in the concentration range of 130–850 
 
µ
 
g/l (17·0–
111 nmol/l) for both methods. The assay detection limit was 30 ng/ml
(3·9 nmol/l). All measurements were performed in a single laboratory.
 
Lipoprotein profiles
 
Serum concentrations of total cholesterol,
 
19
 
 HDL-cholesterol
 
20
 
 and
triglycerides
 
21
 
 were measured as previously described
 
19–21
 
 and
expressed in mmol/l. From these results serum concentrations of
LDL-cholesterol were estimated using Friedewald’s formula.
 
22
 
 All
measurements were performed in a single laboratory.
Long-term reproducibility, measured during a time period of
more than 1 year showed CV of 
 
<
 
 3% in the concentration range of
4–6 mmol/l for total cholesterol, 
 
<
 
 5% in range of 1–2 mmol/l for
HDL-cholestrol, 
 
<
 
 4% in range of 1–2 mmol/l for triglycerides and
 
<
 
 6% for LDL-cholestrol for range estimated from the above CV values.
 
Statistical analysis
 
Baseline data and changes during GH replacement are expressed as
means 
 
±
 
 SD. Comparisons of non-normally distributed data were
performed using the Wilcoxon rank sum test for paired and unpaired
data and normally distributed data were compared using paired and
unpaired Student’s 
 
t
 
-tests as appropriate. Statistical signiﬁcance was
accepted at 
 
P
 
 
 
<
 
  0·05. Correlations between baseline serum lipid
measurements and changes after 12 months of GH replacement were
determined using Pearson correlation coefﬁcients.
 
Results
 
GH dose and serum IGF-I
 
Mean GH dose requirement was slightly but signiﬁcantly lower in
the SG group compared with the NSG group (SG 
 
vs
 
. NSG,
0·32 
 
±
 
 0·178 mg/day 
 
vs
 
. 0·38 
 
±
 
 0·197 mg/day; 
 
P
 
 
 
=
 
 0·0067).
The IGF-I SDS increased signiﬁcantly from –1·4 
 
±
 
 1·37 at baseline
to 0·7 
 
±
 
 1·39 (
 
P
 
 
 
<
 
 0·001) after 12 months of GH treatment in the SG
group and from –1·8 
 
±
 
 1·75 to 0·4 
 
±
 
 1·52 (
 
P
 
 
 
<
 
 0·001) in the NSG group.
 
Baseline serum lipoprotein profiles
 
Concentrations of serum total, LDL- and HDL-cholesterol and
triglycerides prior to commencement of GH replacement therapy
are provided in Table 3. Serum total and LDL-cholesterol were
signiﬁcantly higher in the NSG group (5·8 
 
±
 
 1·15 
 
vs
 
. 5·2 
 
±
 
 1·39 and
3·7 
 
±
 
 1·03 
 
vs
 
. 3·1 
 
±
 
 1·27 mmol/l, respectively; 
 
P
 
 
 
<
 
 0·0001) and serum
triglycerides higher in the SG group (2·0 
 
±
 
 0·73 
 
vs
 
. 1·8 
 
±
 
 0·87 mmol/l;
 
P
 
 
 
<
 
 0·02). Serum HDL-cholesterol concentrations were similar in the
two groups.
 
Changes in serum lipoproteins during GH replacement
 
Serum total and LDL-cholesterol decreased signiﬁcantly in both the
SG and NSG groups during GH replacement (Table 3; Fig. 1). The
decrement in both total and LDL-cholesterol was apparently greater
in the SG group but this did not reach statistical signiﬁcance. No
signiﬁcant changes in HDL-cholesterol or triglycerides were evident
in either group (Table 3). A qualitatively similar pattern of change
in total and LDL-cholesterol was seen in male and female patients in
(a)
(b)
SG NSG
Baseline 1 year Baseline 1 year
Total cholesterol (mmol/l) 5·1 ± 1·24 4·6 ± 0·93 5·7 ± 1·16 5·3 ± 1·08
LDL-cholesterol (mmol/l) 3·1 ± 1·15 2·5 ± 0·87 3·7 ± 1·04 3·4 ± 0·97
HDL-cholesterol (mmol/l) 1·1 ± 0·34 1·1 ± 0·39 1·2 ± 0·33 1·2 ± 0·33
Triglycerides (mmol/l) 2·1 ± 0·75 2·1 ± 1·02 1·8 ± 0·87 1·8 ± 0·87
SG NSG
Baseline 1 year Baseline 1 year
Total cholesterol (mmol/l) 5·3 ± 1·53 4·9 ± 1·08 5·9 ± 1·13 5·6 ± 1·20
LDL-cholesterol (mmol/l) 3·1 ± 1·39 2·6 ± 0·81 3·7 ± 1·03 3·4 ± 1·08
HDL-cholesterol (mmol/l) 1·3 ± 0·29 1·4 ± 0·33 1·4 ± 0·40 1·4 ± 0·40
Triglycerides (mmol/l) 1·9 ± 0·71 1·8 ± 0·90 1·8 ± 0·86 1·8 ± 0·82
Table 3. Measurements of serum total, low 
density lipoprotein (LDL)- and high density 
lipoprotein (HDL)-cholesterol and triglycerides at 
baseline and during 12 months GH replacement 
in statin group (SG) and nonstatin group (NSG) 
in (a) males (b) females (shown as means ± SD)626 J. P. Monson et al.
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both groups but the decrements were signiﬁcantly greater in male
patients in the SG group (Table 3; Figs 2 and 3). A signiﬁcant cor-
relation between baseline measurements and decrements in serum
total cholesterol during GH replacement was evident in both the SG
and NSG groups (R = –0·51, P < 0·001; and R = –0·37, P < 0·001,
respectively). A similar pattern was evident for LDL-cholesterol and
this is demonstrated graphically in Fig. 4.
Discussion
The observed decrements in serum total and LDL-cholesterol in this
study are consistent with previous observations on the beneﬁcial
effects of GH replacement therapy derived from single-centre stud-
ies.
12,13,23 In addition, we have demonstrated that patients already
established on maintenance hypolipidaemic (statin) therapy derive
additional beneﬁt from GH therapy, the data concurring with pre-
vious preliminary observations.
13 Previous analyses of the KIMS
database have demonstrated that the decrement in serum cholesterol
during GH replacement is proportional to baseline cholesterol meas-
urements,
14,24 a phenomenon which is not explained by simple
regression to the mean.
14 In this context, it is noteworthy that the
SG patients in the present study had lower baseline total and LDL-
cholesterol than the NSG patients but nonetheless demonstrated a
statistically equivalent decrement during GH replacement. Indeed
the changes in the SG patients were if anything more striking
although the apparent difference failed to reach statistical signiﬁ-
cance. These ﬁndings raise the possibility that the effects of statins
and GH replacement on serum cholesterol and LDL-cholesterol may
be synergistic rather than simply additive. A particular strength of
our study was the centralized measurement of lipoprotein proﬁles.
Fig. 1 Decrement in serum total and LDL-cholesterol in statin group (SG) 
and nonstatin group (NSG) during 12 months GH replacement. 
Data are shown as mean ± SEM. *P < 0·0004, **P < 0·0001 vs. baseline.
Fig. 2 Decrement in serum total cholesterol in male and female patients in 
statin group (SG) and nonstatin group (NSG) during 12 months GH 
replacement. Data are shown as mean ± SEM. P < 0·01, males vs. females in 
SG.
Fig. 4 Relationship between baseline LDL-
cholesterol and change in LDL-cholesterol in 
(a) statin group (SG), R = –0·54, P < 0·001 and 
(b) nonstatin group (NSG), R = –0·4, P < 0·001.
Fig. 3 Decrement in serum LDL-cholesterol in male and female patients in 
statin group (SG) and nonstatin group (NSG) during 12 months GH 
replacement. Data are shown as mean ± SEM. P < 0·005, males vs. females 
in SG.GH and statin therapy 627
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However, it must be borne in mind that by virtue of the observational
nature of the study we cannot be certain that statin therapy had been
optimized in all patients or that compliance with therapy was abso-
lute. Therefore we cannot exclude the possibility that intensiﬁcation
of statin therapy might have limited the extent to which GH replace-
ment provided an additional hypolipidaemic effect.
The development of glucose intolerance may exert a confounding
effect on the interpretation of longitudinal lipoprotein proﬁle data.
For this reason we excluded from our study all patients who developed
diabetes mellitus during the period of study and extended this to a
further 12 months after completion in order to eliminate the pos-
sibility that a diagnosis of diabetes mellitus had been missed in the
period of observation. Similarly, maintenance of a constant thyrox-
ine replacement dose was a requirement for inclusion in the analysis.
Statin therapy and GH replacement are likely to exert beneﬁcial
effects on serum total and LDL-cholesterol by increasing numbers
of LDL-receptors on hepatocytes although the mechanism underly-
ing this phenomenon differs between the two agents.
25 Therefore an
additive effect on cholesterol lowering would be predicted and has
been conﬁrmed by the present observations. It remains possible that
a synergistic effect may operate and although we observed a numer-
ically greater effect with combined statin and GH therapy, this did
not reach statistical signiﬁcance. Our data indicate that the effects
of GH on serum cholesterol are complementary and at least additive
to those of statin therapy and argue for an important and speciﬁc
effect of GH replacement on cardiovascular risk in adult hypopituitary
patients.
Acknowledgements
The authors express their gratitude to all KIMS investigators for pro-
viding the information on which this analysis was based.
References
1 Rosén, T. & Bengtsson, B.-Å. (1990) Premature mortality due to
cardiovasular disease in hypopituitarism. Lancet, 336, 285–288.
2 Bates, A.S., Van’t Hoff, W., Jones, P.J. & Clayton, R.N. (1996) The effect
of hypopituitarism on life expectancy. Journal of Clinical Endocrinology
and Metabolism, 81, 1169–1172.
3 Bülow, B., Hagmar, L., Mikoczy, Z., Nordström, C.H. & Erfurth, E.M.
(1997) Increased cerebrovascular mortality in patients with hypo-
pituitarism. Journal of Clinical Endocrinology and Metabolism, 46, 75–81.
4 Svensson, J., Bengtsson, B.-Å., Rosén, T., Oden, A. & Johannsson, G.
(2004) Malignant disease and cardiovascular morbidity in hypo-
pituitary adults with or without growth hormone replacement therapy.
Journal of Clinical Endocrinology and Metabolism, 89, 3306–3312.
5 Tomlinson, J.W., Holden, N., Hills, R.K., Wheatley, K., Clayton, R.N.,
Bates, A.S., Sheppard, M.C. & Stewart, P.M. (2001) Association between
premature mortality and hypopituitarism. Lancet, 357, 425–431.
6 Salomon, F., Cuneo, R.C., Hesp, R. & Sönksen, P.H. (1989) The effects
of treatment with recombinant human growth hormone on body
composition and metabolism in adults with growth hormone
deﬁciency. New England Journal of Medicine, 321, 1797–1803.
7 Beshyah, S.A. & Johnston, D. (1999) Cardiovasular disease and risk
factors in adults with hypopituitarism. Clinical Endocrinology, 50, 1–15.
8 Abs, R., Bengtsson, B.-Å., Hernberg-Ståhl, E., Monson, J.P.,
Tauber, J.-P., Wilton, P. & Wüster, C. (1999) GH replacement in 1034
growth hormone deﬁcient adults: demographic and clinical results,
dosing and safety. Clinical Endocrinology, 50, 703–713.
9 Abdu, T.A., Neary, R., Elhadd, T.A., Akber, M. & Clayton, R.N. (2001)
Coronary risk in growth hormone deﬁcient hypopituitary adults:
increased predicted risk is due largely to lipid proﬁle abnormalities.
Clinical Endocrinology, 55, 209–216.
10 Jørgensen, J.O., Pedersen, S.A., Thuesen, L., Jorgensen, J., Ingemann-
Hansen, T., Skakkebaek, N.E. & Christiansen, J.S. (1989) Beneﬁcial
effects of growth hormone treatment in GH-deﬁcient adults. Lancet,
1, 1221–1225.
11 Markussis, V., Beshyah, S.A., Fisher, C., Sharp, P., Nicholaides, A.N.
& Johnston, D. (1992) Detection of premature atherosclerosis by high
resolution ultrasonography in symptom free hypopituitary adults.
Lancet, 340, 1188–1192.
12 Weaver, J.U., Monson, J.P., Noonan, K., John, W.G., Edwards, A.,
Evans, K.A. & Cunningham, J.C. (1995) The effect of low dose
recombinant human growth hormone replacement on regional fat
distribution, insulin sensitivity and cardiovascular risk factors in
hypopituitary adults. Journal of Clinical Endocrinology and Metabolism,
80, 153–159.
13 Florakis, D., Hung, V., Kaltsas, G., Coyte, D., Jenkins, P.J., Chew, S.L.,
Grossman, A.B., Besser, G.M. & Monson, J.P. (2000) Sustained
reduction in circulating cholesterol in adult hypopituitary patients
given low dose titrated growth hormone replacement therapy: a
two-year study. Clinical Endocrinology, 53, 453–459.
14 Abs, R., Feldt-Rasmussen, U., Bengtsson, B.-Å., Goth, M.I., Monson, J.P.,
Koltowska-Häggström, M., Mattsson, A.F. & Wilton, P. (2006) Deter-
minants of cardiovascular risk in 2589 hypopituitary GH-deﬁcient
adults – a KIMS database analysis. European Journal of Endocrinology,
155, 79–90.
15 Abs, R., Bengtsson, B.-Å., Feldt-Rasmussen, U., Goth, M.,
Monson, J.P., Verhelst, J., Koltowska-Häggström, M., Mattson, A.F.,
Westberg, B. & Wilton, P. (2005) The clinical characteristics and
responses to GH replacement in adults with isolated growth hor-
mone deﬁciency are indistinguishable from those in conventionally
replaced hypopituitary adults. Growth Hormone & IGF Research, 15,
349–359.
16 Waterhouse, M., Laureiro, R., Walker, D., Besser, G.M. & Monson, J.P.
(2003) Baseline clinical characteristics and response to growth hor-
mone replacement therapy in adults with isolated growth hormone
deﬁciency in comparison with multiple pituitary hormone deﬁciencies.
Endocrine Abstracts, 5, P91.
17 Colson, A., Brooke, A.M., Walker, D., Besser, G.M., Chew, S.L.,
Grossman, A.B., Jenkins, P.J., Drake, W.M. & Monson, J.P. (2006)
Growth hormone deﬁciency and replacement in patients with
treated Cushing’s disease, prolactinomas and non-functioning
pituitary adenomas: effects on body composition, glucose metabo-
lism, lipid status and bone mineral density. Hormone Research, 66,
257–267.
18 Brabant, G., von zur Mühlen, A., Ranke, M.B., Kratzsch, J., Kiess, W.,
Ketelslegers, J.M., Wilhelmsen, L., Hulthen, L., Saller, B., Mattsson, A.,
Wilde, J., Schemer, R., Kann, P. & German Board, K.I.M.S. (2003)
Serum insulin-like growth factor I reference values for an automated
chemiluminescence immunoassay system: results from a multicentre
study. Hormone Research, 60, 53–60.
19 Lie, R.F., Schmitz, J.M., Pierre, K.J. & Gochman, N. (1976) Cholesterol
oxidase-based determination, by continuous ﬂow analysis, of total
and free cholesterol in serum. Clinical Chemistry, 22, 1627–1630.
20 Lopes-Virella, M.F., Stone, P., Ellis, S. & Colwell, J.A. (1977) Choles-
terol determination in high-density lipoproteins separated by three
different methods. Clinical Chemistry, 23, 882–884.628 J. P. Monson et al.
© 2007 The Authors
Journal compilation © 2007 Blackwell Publishing Ltd, Clinical Endocrinology, 67, 623–628
21 Fossati, P. & Prencipe, L. (1982) Serum triglyceride determined
colorimetrically with an enzyme that produces hydrogen peroxide.
Clinical Chemistry, 28, 2077–2080.
22 Friedewald, W.T., Levy, R.I. & Fredrickson, D.S. (1972) Estimation
of the concentration of low-density lipoprotein cholesterol in plasma,
without use of the preparative ultracentrifuge. Clinical Chemistry, 18,
499–502.
23 Cuneo, R.C., Salomon, F., Watts, G.F., Hesp, R. & Sönksen, P.H. (1993)
Growth hormone treatment improves serum lipids and lipoproteins
in adults with growth hormone deﬁency. Metabolism, 42, 1519–1523.
24 Bengtsson, B.-Å., Abs, R., Bennmarker, H., Monson, J.P.,
Feldt-Rasmussen, U., Hernberg-Ståhl, E., Westberg, B., Wilton, P.
& Wüster, C. (1999) The effects of treatment and the individual
responsiveness to GH replacement therapy in 665 GH-deﬁcient adults.
Journal of Clinical Endocrinology and Metabolism, 84, 3929–3935.
25 Lind, S., Rudling, M., Ericsson, S., Olivecrona, H., Eriksson, M.,
Borgstrom, B., Eggertsen, G., Berglund, L. & Angelin, B. (2004)
Growth hormone induces low-density lipoprotein clearance but
not bile acid synthesis in humans. Arteriosclerosis, Thrombosis and
Vascular Biology, 24, 349–356.